Skip to search formSkip to main contentSkip to account menu

patiromer

Known as: Patiromer FOS 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (1)

Polymers

Narrower (2)

RLY 5016Veltassa
patiromer 25200 MG Powder for Oral Suspension [Veltassa]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Case report: Patiromer-induced hypercalcemia
Patiromer is a novel potassium-binding compound which has recently received FDA approval. This ion exchange resin releases… 
Review
2019
Review
2019
New therapies for hyperkalemia
Purpose of review Although renin–angiotensin aldosterone system (RAAS) inhibitors have become the mainstay treatment for patients… 
2017
2017
Evaluation of the Pharmacodynamic Effects of the Potassium Binder RDX7675 in Mice
Introduction: Hyperkalemia is a common complication in patients with heart failure or chronic kidney disease, particularly those… 
2017
2017
The Management of Co-Morbidities in Patients with Heart Failure – Potassium Balance
Both hypokalaemia and hyperkalaemia are common in HF patients. They are each associated both with HF and with the many drugs used… 
2016
2016
Patiromer Decreases Serum Potassium and Phosphate Levels in Patients on Hemodialysis.
BACKGROUND Persistent hyperkalemia (serum potassium (K) ≥5.5 mEq/l) is a common condition in hemodialysis (HD) patients, is… 
2016
2016
OS 19-04 CHRONIC DIURETIC THERAPY DOES NOT IMPAIR THE EFFECTIVENESS OF PATIROMER IN HYPERKALEMIC PATIENTS WITH CKD
Objective: Diuretics, alone or in combination, are frequently prescribed in chronic kidney disease (CKD) and heart failure (HF… 
2016
2016
OS 19-02 RELATIONSHIP BETWEEN VISIT-TO-VISIT BLOOD PRESSURE VARIABILITY (BPV) AND KIDNEY FUNCTION IN PATIENTS WITH HYPERTENSION
Objective: High blood pressure variability (BPV) and worsening kidney function have both independently been linked to a higher… 
2015
2015
Sodium zirconium cyclosilicate (ZS-9) treatment in patients with serum potassium >6.5 mEq/L
No abstract available. (Published: 1 September 2015) This paper has been commented by Paras Karmacharya et al. Please read the… 
2015
2015
Effects of the norepinephrine prodrug droxidopa - a novel treatment for neurogenic orthostatic hypotension - on cardiac repolarization
2015
2015
Clinical trials: New nonabsorbable potassium-exchange resins in hyperkalaemia
New data suggest that treatment with patiromer or sodium zirconium cyclosilicate for up to 8 weeks reduces plasma potassium… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)